AMGN
AMGEN INC
Nasdaq: AMGN · Thousand Oaks, CA · Healthcare
$439.26-8.02 (-1.79%)Closed
Market Cap$237.46B
Cash$13.99Bmost recent
Runwayprofitable
P/E (TTM)30.9EPS $14.23
52-Wk Range$283.30 – $447.28
Avg Volume2.8M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$439.26+47.8%
Pipeline

Drug candidates sponsored by AMGEN · ClinicalTrials.gov

67 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4cinacalcet
Chronic Kidney Disease+11 more
Completed
2009-05past
2
Phase 4darbepoetin alfa
Chronic Kidney Disease+9 more
Completed
2012-04past
6
Phase 4Etanercept
Psoriatic Arthritis+2 more
Completed
2012-12past
5
Phase 4VIMOVO 250/20
Juvenile Idiopathic Arthritis (JIA)
Completed
2015-02past
1
Phase 4Ivabradine
Heart Failure (HF)
Completed
2019-04-19past
1
Phase 4Evolocumab
Cardiovascular Disease+10 more
Active, not recruiting
2027-05-29
6
Phase 4Apremilast
Psoriasis+7 more
Recruiting
2028-03-21
8
Phase 3AMG 073
Secondary Hyperparathyroidism+1 more
Completed
2003-03past
1
Phase 3AMG 162
Low Bone Mineral Density
Completed
2011-03-28past
1
Phase 3Cetuximab
Metastatic Colorectal Cancer
Completed
2013-02-05past
1
Phase 3Evolocumab AMD
Primary Hypercholesterolemia+1 more
Completed
2013-11-15past
1
Phase 3Etanercept / Autoinjector A
Rheumatoid Arthritis+1 more
Completed
2013-12-18past
1
Phase 3AMG386 plus PLD
Fallopian Tube Cancer+2 more
Terminated
2014-08-29past
1
Phase 3Etelcalcetide
Hyperparathyroidism, Secondary
Completed
2015-07-01past
3
Phase 3Carboplatin
Non-small Cell Lung Cancer Metastatic
Completed
2015-07-23past
1
Phase 3Erenumab
Migraine+1 more
Completed
2020-03-16past
3
Phase 3Denosumab
Cancer+6 more
Completed
2022-03-26past
2
Phase 3Apremilast (CC-10004)
Psoriasis
Completed
2022-04-25past
1
Phase 3Carfilzomib
Relapsed or Refractory Multiple Myeloma+2 more
Completed
2023-03-31past
2
Phase 3Teprotumumab
Thyroid Eye Disease+2 more
Completed
2025-11-22past
2
Phase 3Rocatinlimab
Atopic Dermatitis
Terminated
2026-07-01past
1
Phase 3ABP 938 8 mg
Neovascular Age-related Macular Degeneration+1 more
Recruiting
2027-07-31
1
Phase 3ABP 206
Melanoma
Active, not recruiting
2028-01-25
1
Phase 3Unnamed
Osteogenesis Imperfecta
Recruiting
2028-04-19
1
Phase 3Xaluritamig
Metastatic Castration-resistant Prostate Cancer+1 more
Recruiting
2029-01-02
2
Phase 2Romiplostim
Idiopathic Thrombocytopenic Purpura+1 more
Completed
2004-07-19past
2
Phase 2AMG 706
Gastrointestinal Cancer
Completed
2006-06past
1
Phase 2AMG 162 180 mg (SC) q 12 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer+2 more
Completed
2008-01past
1
Phase 2Antizol
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Completed
2008-06past
1
Phase 2AMG 827
Rheumatoid Arthritis
Terminated
2011-04-05past
1
Phase 2Sunitinib
Advanced Renal Cell Carcinoma
Completed
2011-08-08past
1
Phase 2Brodalumab
Crohn's Disease
Terminated
2011-10-18past
1
Phase 2Apremilast 30 mg
Rheumatoid Arthritis
Terminated
2012-02-21past
1
Phase 2Blinatumomab
Diffuse Large B-cell Lymphoma
Completed
2014-07past
1
Phase 2Brodalumab 210 mg
Axial Spondyloarthritis
Withdrawn
2015-05past
1
Phase 2Placebo
Asthma
Completed
2015-05-15past
2
Phase 2CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
ANCA-associated Vasculitis
Completed
2016-04-24past
1
Phase 2Talimogene Laherparepvec
Unresected Stage IIIb to IVM1c Melanoma
Completed
2017-06-26past
1
Phase 2Inebilizumab
Highly Sensitized Patients on Waiting List for Kidney Transplantation
Withdrawn
2021-12past
1
Phase 2Sotorasib
Non-small Cell Lung Cancer
Terminated
2025-05-28past
1
Phase 2Tarlatamab
Small Cell Lung Cancer (SCLC)
Active, not recruiting
2029-08-10
1
Phase 2AMG 714
Rheumatoid Arthritis
Completed—1
Phase 2filgrastim
Pain+1 more
Unknown—1
Phase 1Unnamed
Healthy Men and Women
Completed
2004-10past
1
Phase 1CCX168
Vasculitis+1 more
Completed
2010-09-19past
1
Phase 1[¹⁴C]Etelcalcetide
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Completed
2014-04-15past
1
Phase 1AMG 282
Chronic Rhinosinusitis With Nasal Polyps
Completed
2016-05past
1
Phase 1AMG 397
Multiple Myeloma+6 more
Terminated
2019-07-25past
1
Phase 1AMG 330
Relapsed or Refractory Acute Myeloid Leukemia
Terminated
2020-10-23past
1
Phase 1TEPEZZA
Bioavailability+1 more
Completed
2021-05-27past
1
Phase 1AMG 171
Obesity
Terminated
2021-09-10past
1
Phase 1ABP 501-HCF
Adalimumab
Completed
2021-11-24past
1
Phase 1Immediate Release (IR) Formulation
Relapsed or Refractory Multiple Myeloma
Completed
2022-10-06past
1
Phase 1AMG 199
MUC17-positive Solid Tumors
Terminated
2023-06-01past
1
Phase 1AMG 256
Advanced Solid Tumors
Completed
2023-09-21past
1
Phase 1Olpasiran
Elevated Serum Lipoprotein(a)+1 more
Completed
2024-11-29past
2
Phase 1Maridebart cafraglutide
Type 2 Diabetes Mellitus
Active, not recruiting
2026-11-15
1
Early Phase 1Emerfetamab
Acute Myeloid Leukemia
Terminated
2020-12-28past
1
N/ASafety observation
Idiopathic Parkinson's Disease
Completed
2006-11past
1
N/AUnnamed
Non-Hodgkin's Lymphoma
Completed
2008-12past
1
N/AUnnamed
Breast Cancer+3 more
Completed
2009-10past
1
N/ANot applicable- observational study
Birth Defect+2 more
Terminated
2014-01past
1
N/AUnnamed
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Completed
2015-01-22past
1
N/AUnnamed
Atherosclerotic Cardiovascular Disease
Completed
2023-12-30past
1
N/AEnbrel®
Rheumatoid Arthritis
Completed—1
N/AAMG 701
n/a
No Longer Available—1
N/ATrifluridine
Mycobacterium Avium-Intracellulare Infection+1 more
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.